Department of Obstetrics and Gynecology, El-Shatby Maternity University Hospital, University of Alexandria, Port Said Street, El Shatby, Alexandria 21526, Egypt.
BMC Cancer. 2014 Mar 28;14:227. doi: 10.1186/1471-2407-14-227.
Less than 1% of all breast cancer cases are found in men, who reportedly have inferior outcomes compared with matched women patients. Ethnic differences may also affect their prognosis. Here, we investigated overall survival (OS) and major prognostic factors for male breast cancer (MBC) in a cohort of Egyptian patients.
We retrospectively analyzed OS in a cohort of 69 male patients with MBC who were surgically treated at the Mansoura Cancer Center, Egypt between 2000 and 2007. We registered demographic data, age, height, weight and body mass index, tumor size, histology, number of infiltrated axillary lymph nodes, hormone receptor (HR) status and metastatic presence, and TNM staging. Patients' OS was the primary endpoint. Patients received treatment to the medical standards at the time of their diagnosis.
In the 69 patients who met the inclusion criteria and had complete stored patient data, tumors ranged from T1c to T3. We could gather cancer-related survival data from only 56 patients. The collective 5-year survival in this cohort was 46.4%. Only five patients had distant metastasis at diagnosis, but they showed a null percent 5-year survival, whereas those with no lymph node infiltration showed a 100% 5-year survival. Lymph node status and tumor grading were the only prognostic factors that significantly affected OS.
Lymph node status and tumor grade are the most important prognostic factors for overall survival of MBC in Egyptian male patients; whereas even remarkably low HR expression in MBC did not significantly affect OS. Further research is needed to understand the factors that affect this disease.
男性乳腺癌的发病率不足所有乳腺癌病例的 1%,据报道,与匹配的女性患者相比,他们的预后较差。种族差异也可能影响他们的预后。在这里,我们调查了埃及患者队列中男性乳腺癌(MBC)的总生存率(OS)和主要预后因素。
我们回顾性分析了 2000 年至 2007 年在埃及曼苏拉癌症中心接受手术治疗的 69 例男性 MBC 患者的 OS。我们记录了人口统计学数据、年龄、身高、体重和体重指数、肿瘤大小、组织学、浸润腋窝淋巴结的数量、激素受体(HR)状态和转移性存在以及 TNM 分期。患者的 OS 是主要终点。患者接受了诊断时的医疗标准治疗。
在符合纳入标准且有完整存储患者数据的 69 名患者中,肿瘤范围从 T1c 到 T3。我们只能从 56 名患者中收集到癌症相关的生存数据。该队列的 5 年总生存率为 46.4%。只有 5 名患者在诊断时就有远处转移,但他们的 5 年生存率为 0%,而无淋巴结浸润的患者的 5 年生存率为 100%。淋巴结状态和肿瘤分级是唯一显著影响 OS 的预后因素。
淋巴结状态和肿瘤分级是影响埃及男性 MBC 患者总体生存率的最重要预后因素;而 MBC 中即使 HR 表达极低也不会显著影响 OS。需要进一步研究以了解影响这种疾病的因素。